

Suneil Jain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1163012/publications.pdf>

Version: 2024-02-01

103
papers

7,439
citations

159585

30
h-index

60623

81
g-index

110
all docs

110
docs citations

110
times ranked

10338
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers. <i>Radiation Oncology</i> , 2022, 17, 38.	2.7	0
2	Murine models of radiation cardiotoxicity: A systematic review and recommendations for future studies. <i>Radiotherapy and Oncology</i> , 2022, 173, 19-31.	0.6	15
3	Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics. <i>Cancer Letters</i> , 2021, 498, 210-216.	7.2	9
4	The stereotactic prostate radiotherapy (SPORT) trial: A randomized feasibility study comparing prostate SABR to prostate and pelvic nodal SABR.. <i>Journal of Clinical Oncology</i> , 2021, 39, 248-248.	1.6	2
5	Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells. <i>Scientific Reports</i> , 2021, 11, 4252.	3.3	9
6	Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1055-1062.	3.9	4
7	A novel artefacts removal technique for prostate CT-based radiomics analysis. <i>Physica Medica</i> , 2021, 84, 299.	0.7	0
8	Brachytherapy Boost in Prostate Cancer: What Does Observational Data Add to the Debate?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1230-1231.	0.8	0
9	Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK urooncologists. <i>International Journal of Clinical Practice</i> , 2021, 75, e14338.	1.7	1
10	Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4549-4556.	7.0	5
11	Abstract 162: Cholesterol metabolism gene expression and prostate cancer-specific outcomes in radiotherapy-treated patients. , 2021, , .		0
12	Efficacy, Use, and Acceptability of a Web-Based Self-management Intervention Designed to Maximize Sexual Well-being in Men Living With Prostate Cancer: Single-Arm Experimental Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e21502.	4.3	3
13	Effects of a Brief E-Learning Resource on Sexual Attitudes and Beliefs of Healthcare Professionals Working in Prostate Cancer Care: A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10045.	2.6	4
14	3D-printed patient-specific pelvis phantom for dosimetry measurements for prostate stereotactic radiotherapy with dominant intraprostatic lesion boost. <i>Physica Medica</i> , 2021, 92, 8-14.	0.7	8
15	miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. <i>Cancer Letters</i> , 2020, 473, 107-117.	7.2	33
16	The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. <i>Epidemiology</i> , 2020, 31, 432-440.	2.7	22
17	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	10.7	450
18	Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqaa062.	3.2	0

#	ARTICLE	IF	CITATIONS
19	The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs. <i>Nature Reviews Urology</i> , 2020, 17, 499-512.	3.8	15
20	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. <i>NAR Cancer</i> , 2020, 2, zcaa012.	3.1	8
21	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	1.9	101
22	Development of a conceptual framework to improve sexual wellbeing communication in routine prostate cancer care. <i>Patient Education and Counseling</i> , 2020, 103, 1150-1160.	2.2	6
23	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996.	1.6	107
24	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 1743-1751.	8.2	180
25	The Tablet-Based, Engagement, Assessment, Support, and Sign-Posting (EASSi) Tool for Facilitating and Structuring Sexual Well-Being Conversations in Routine Prostate Cancer Care: Mixed-Methods Study. <i>JMIR Cancer</i> , 2020, 6, e20137.	2.4	3
26	Results of the ADRRAD Trial of pelvic IMRT plus radium-223 in men with mHSPC metastatic to bone.. <i>Journal of Clinical Oncology</i> , 2020, 38, 136-136.	1.6	0
27	Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. <i>Cancers</i> , 2020, 12, 2804.	3.7	8
28	Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 448-456.	0.8	41
29	Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1066-1073.	0.8	9
30	Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT). <i>Pilot and Feasibility Studies</i> , 2019, 5, 102.	1.2	8
31	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1531-1543.	10.7	362
32	A pilot study of patient reported outcomes evaluating treatment related symptoms and quality of life for men receiving high dose rate brachytherapy combined with hypo-fractionated radiotherapy or hypo-fractionated radiotherapy alone for the treatment of localised prostate cancer. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 9, 18-25.	1.9	3
33	Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S26.	0.3	0
34	Observed high incidence of prostatic calculi with the potential to act as natural fiducials for prostate image guided radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 9, 35-40.	1.9	5
35	Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S96.	0.3	0
36	Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging. <i>Radiation Oncology</i> , 2019, 14, 237.	2.7	13

#	ARTICLE	IF	CITATIONS
37	An evaluation of techniques for dose calculation on cone beam computed tomography. British Journal of Radiology, 2019, 92, 20180383.	2.2	49
38	TOPARP-B: A phase II randomized trial of the poly(ADP-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. Journal of Clinical Oncology, 2019, 37, 5005-5005.	1.6	35
39	PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).. Journal of Clinical Oncology, 2019, 37, 1-1.	1.6	18
40	Plasma citrulline levels as a biomarker for bowel toxicity in prostate stereotactic radiotherapy with or without pelvic nodal radiation.. Journal of Clinical Oncology, 2019, 37, 73-73.	1.6	0
41	Toxicity results from a novel phase I/II trial of VMAT radiotherapy to prostate and pelvic nodes plus six cycles of radium-223 in mCSPC metastatic to bone post ADT and docetaxel.. Journal of Clinical Oncology, 2019, 37, 196-196.	1.6	0
42	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 2019, 9, e034708.	1.9	2
43	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 2019, 9, e034708.	1.9	6
44	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	6.1	132
45	Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Annals of Oncology, 2018, 29, 215-222.	1.2	86
46	UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clinical Oncology, 2018, 30, 5-14.	1.4	191
47	Efficacy of a rectal spacer with prostate SABRâ€™first UK experience. British Journal of Radiology, 2018, 91, 20170672.	2.2	11
48	TRUFU: Therapeutic radiographer undertaking follow up for prostate cancer patients. Radiography, 2018, 24, 298-303.	2.1	4
49	Impact and practical aspects of rectal spacer insertion for prostate stereotactic radiotherapyâ€™first UK experience. European Journal of Surgical Oncology, 2018, 44, S34.	1.0	0
50	The Effect of Bilateral Treatment Plan Symmetry on Postoperative Dosimetric Outcomes in Prostate Low-Dose-Rate Brachytherapy: A Single-Institution Study. Brachytherapy, 2018, 17, S83.	0.5	0
51	UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016. Journal of Contemporary Brachytherapy, 2018, 10, 238-245.	0.9	7
52	Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5013-5013.	1.6	5
53	CASPIR trial: Using prostatic calculi as an alternative to fiducial markers for IGRT in for localized prostate cancer.. Journal of Clinical Oncology, 2018, 36, 60-60.	1.6	1
54	Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer.. Journal of Clinical Oncology, 2018, 36, 5-5.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Changing trends in prostate brachytherapy practice for clinically localized prostate cancer: Results of a survey in UK and Ireland.. Journal of Clinical Oncology, 2018, 36, 16-16.	1.6	0
56	Abstract 290: Integrative analytics: A framework for precision medicine. , 2018, , .		0
57	Abstract B035: Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis. , 2018, , .		0
58	An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology. Cancer Nanotechnology, 2017, 8, 3.	3.7	12
59	Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter. International Journal of Radiation Oncology Biology Physics, 2017, 98, 419-427.	0.8	52
60	Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. Radiation Oncology, 2017, 12, 53.	2.7	6
61	Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy. Brachytherapy, 2017, 16, S36-S37.	0.5	1
62	Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 822-829.	0.8	50
63	Impact and practical aspects of rectal spacer insertion for prostate stereotactic radiotherapy â€œ First UK experience. European Journal of Surgical Oncology, 2017, 43, 2231.	1.0	0
64	Managing cardiovascular risk in highâ€risk prostate cancer. Trends in Urology & Men's Health, 2017, 8, 13-18.	0.4	1
65	A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy. Radiation Oncology, 2017, 12, 124.	2.7	9
66	A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment.. Journal of Clinical Oncology, 2017, 35, 11-11.	1.6	1
67	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. Journal of Clinical Oncology, 2017, 35, 141-141.	1.6	2
68	A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment.. Journal of Clinical Oncology, 2017, 35, 11-11.	1.6	0
69	Reply to J.J. Tosoian et al. Journal of Clinical Oncology, 2016, 34, 4453-4453.	1.6	0
70	SPORT high-risk trial: A randomised feasibility study evaluating stereotactic prostate radiotherapy in high-risk localised prostate cancer with or without elective nodal irradiation. European Journal of Surgical Oncology, 2016, 42, S235.	1.0	1
71	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Journal of Oncology Practice, 2016, 12, 267-269.	2.5	11
72	Fiducial marker guided prostate radiotherapy: a review. British Journal of Radiology, 2016, 89, 20160296.	2.2	68

#	ARTICLE	IF	CITATIONS
73	Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. <i>Journal of Urology</i> , 2016, 196, 1651-1658.	0.4	157
74	Imaging and radiation effects of gold nanoparticles in tumour cells. <i>Scientific Reports</i> , 2016, 6, 19442.	3.3	111
75	Class solutions for SABR-VMAT for high-risk prostate cancer with and without elective nodal irradiation. <i>Radiation Oncology</i> , 2016, 11, 155.	2.7	9
76	A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 118, 478-484.	0.6	22
77	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj <i>Clinical Oncology</i> , 2016, 34, 2182-2190.	1.6	285
78	Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy. <i>British Journal of Radiology</i> , 2015, 88, 20150256.	2.2	10
79	Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. <i>Journal of Urology</i> , 2015, 194, 79-84.	0.4	68
80	Cellular signalling effects in high precision radiotherapy. <i>Physics in Medicine and Biology</i> , 2015, 60, 4551-4564.	3.0	15
81	Conventional in vivo irradiation procedures are insufficient to accurately determine tumor responses to non-uniform radiation fields. <i>International Journal of Radiation Biology</i> , 2015, 91, 257-261.	1.8	5
82	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
83	Sector analysis provides additional spatial information on the permanent prostate brachytherapy learning curve. <i>Brachytherapy</i> , 2015, 14, 703-710.	0.5	2
84	Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 272-277.	1.6	985
85	Cautionary tale of active surveillance in intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 163-163.	1.6	4
86	Sector analysis to provide additional spatial information on the permanent prostate brachytherapy learning curve.. <i>Journal of Clinical Oncology</i> , 2015, 33, 93-93.	1.6	7
87	Comparison of active surveillance with other treatment options for low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 178-178.	1.6	0
88	Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. <i>Radiotherapy and Oncology</i> , 2014, 110, 342-347.	0.6	72
89	A sector-based postimplant dosimetric comparison of sagittal and axial ultrasound-guided source placement during I-125 permanent prostate brachytherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 262-262.	1.6	0
90	Management of Bartholin's gland carcinoma using high-dose-rate interstitial brachytherapy boost. <i>Brachytherapy</i> , 2013, 12, 500-507.	0.5	3

#	ARTICLE	IF	CITATIONS
91	Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11days: A comparison of acute toxicity and quality of life. Radiotherapy and Oncology, 2013, 108, 320-325.	0.6	39
92	Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. Radiotherapy and Oncology, 2013, 107, 153-158.	0.6	156
93	Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.. Journal of Clinical Oncology, 2013, 31, 1-1.	1.6	2
94	Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles. International Journal of Nanomedicine, 2012, 7, 2673.	6.7	150
95	The effect of radiation technique and bladder filling on the acute toxicity of pelvic radiotherapy for localized high risk prostate cancer. Radiotherapy and Oncology, 2012, 105, 193-197.	0.6	26
96	Comparison of acute toxicity in patients treated with a 4-field box or IMRT to deliver elective pelvic nodal irradiation for localized high-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 69-69.	1.6	0
97	Biochemical, pathologic, toxicity, and quality-of-life outcomes in a five-fraction hypofractionated accelerated radiotherapy treatment using standard linear accelerators and gold seed fiducials.. Journal of Clinical Oncology, 2012, 30, 186-186.	1.6	1
98	Energy Dependence of Gold Nanoparticle Radiosensitization in Plasmid DNA. Journal of Physical Chemistry C, 2011, 115, 20160-20167.	3.1	50
99	Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiotherapy and Oncology, 2011, 100, 412-416.	0.6	174
100	Cell-Specific Radiosensitization by Gold Nanoparticles at Megavoltage Radiation Energies. International Journal of Radiation Oncology Biology Physics, 2011, 79, 531-539.	0.8	388
101	Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Scientific Reports, 2011, 1, 18.	3.3	335
102	Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy. Nanotechnology, 2010, 21, 295101.	2.6	194
103	Radiotherapy in the presence of contrast agents: a general figure of merit and its application to gold nanoparticles. Physics in Medicine and Biology, 2008, 53, 5635-5651.	3.0	173